SLS

ElmoLovesGrover

Biotechs I like SLS, SPRO, SCYX, baby

CalabreseAlsatian

SLS trials lasting longer is a good sign GPS works. Patience, grasshopper.

Quiet-Classic7496

I also vote SLS!

JackFourj4

Viking Therapeutics (VKTX) had the best weight loss data in their phase2 trial, better dan Novo and Lilly. They will either go it alone and become part of the obesity gravy train, or more likely, will soon be bought by a big pharma company for at least 4x the current sp. Sellas Life Sciences (SLS) has an imminent readout of their phase 3 trial in acute myeloid leukemia, which will very likely 10x the current sp in a buyout or 2y after launch of their therapy

aohallx

congrats my friend. i joined you last month @ a hundred bc college student. any other plays? i’m in on SLS heavy

thepoisonpoodle

Put your money in NFE. Then wait to 60 then go to SLS. Wait for 50. Then go to your account and cash out. Delete it. And live a happy life.

Msilverthorpe

SLS if the Phase 3 trial in acute myeloid leukemia (AML) is successful. Market cap of \~220m, \~20% of the float is short. The trial results are supposed to be unblinded upon the 80th death (125 patients in the trial). The 60th death was in early Dec 2024 and it was believed at that time that the 80th death would happen this past summer. SLS longs believe that it's taking longer to happen because the drug galinpepimut-S (aka GPS) is keeping patients in the treatment arm alive longer than originally expected.

Prestigious-Duck-189

SLS

Orange_Codex

WWR is in a very good position to build graphite mine and production facilities. I know people forgot about them after the critical minerals rally, but don't underestimate their position. PLSR plans ten new appraisal wells, which is a bit insane but mostly funded by warrants that have already been exercised. With an 1,000% increase in land assets near their Topaz project (on continuant geology), it is very unlikely any near-future appraisals will underwhelm. SLS is going to help me buy an island. No doubt whatsoever. Its drug (GPS) is for survivability, and data release is triggered by the eightieth patient death. The longer it takes to release data, the better the chance of that data being good. It's already a year overdue. AZTR is also in my port. No idea what its chances of good Phase II results are (haven't read the science), but it's such a small float a stiff breeze could trigger a multi-bag run. Still bullish on HUI (HUIPF) too. There's something very attractive about the company's recent momentum and unique strategic vision. They know *why* past stock performance is poor and seem to know exactly what to do to address it. Huge float, but mostly locked-up. Underrated potential for swings.

Orange_Codex

Bright green earlier today. Now a little red. Still not buying or selling *anything* until SLS or AZTR pop.

Glass_Crazy_3996

The inducement warrants themselves could be valuable if SLS performs well — the holders have optionality.

Glass_Crazy_3996

Well, let’s look at it this way if you will- If an investor is bullish on SLS’s clinical programs, its cancer therapies, they may view the cash infusion as a positive — it gives the company runway to hit milestones. So there is financial logic here when it comes to operating…

Orange_Codex

Just waiting for SLS, AZTR, and PLSR news to drop. Whole market's either a falling knife or a bull trap and I don't care to find out which.

Prestigious-Duck-189

Well said! On the positive side, Sellas isn’t 100% binary because there’s a second asset in the pipeline. So when GPS fails there might be some sort of safety net due to the value of SLS009 and the cash balance. It won’t be astronomical anymore because we’d miss the platform proposition we now have with two assets. But still value. This, in my opinion, makes the downside at the current price level a bit smaller compared to a pure binary event. That being said, the science so far tells us the chances of a positive readout are far greater than a failure of GPS🤞🏼

Regular_Hawk8513

SLS worth it??

Orange_Codex

I second what he said. SLS's lead drug (GPUS) is the closest thing we have to an effective general cancer treatment.

Orange_Codex

SLS and AZTR are my Q4 biotech plays. SLS has a far better product and prospects, but AZTR's float is tiny - even moderate results will send it up 200-300%. PLSR is also dropping new appraisals soon. If their helium-3 scales up with recent land purchases (i.e. +1,000%), we enter the fusion age and they become a three comma company in waiting. Next month, I plan to take big positions in HUI (Hydrogen Utopia International) and either ASX:EOS or INTS depending on the current state of INTS's cash flow. I'm still mad I sold INTS two weeks before it ran 600%. That's the last time I let reserve split fears shake me out.

shaqballs

SLS could make millionaires before Christmas

Oh-The-Horrorr

And you're in on SLS? 😬I wish you luck sir

Kosem75

Im in for SLS and Ganx

shaqballs

Good post OP. Very informative for newbies. Ignore this poster though ^^ anyone that comments about share price in a BINARY INVESTMENT doesn’t know a thing in what they are talking about. SLS is a game changer that will transform the AML treatment landscape. They have two home run drugs that will either make millionaires or new Wendy’s employees. The data leads towards the first option. It’s easy to do a little bit of research and decide if it’s worth taking a gamble on the stock but current price action doesn’t mean shit. The ceo diluted a while ago after a pump which was idiotic and unnecessary and has people pissed off which is fair. Now they have cash runway for like three years and are gearing up to sell their company once the 80th event happens (by the end of the year they predict) and top line data shortly after. Based off most people’s math the buyout could fetch somewhere between 5b-20b which would roughly be 20x your money to 80x. Once again there is so much risk in the company but the upside greatly outweighs the downside. The management is stupid but all that matters is that the drugs work. If GPS (the main drug with the nearest catalyst) fails (which it won’t) the stock price will probably be cut in half. Thankfully for SLS they have a backup drug SLS-009 which has shown significant promise aswell and could save the company if GPS fails. The most likely outcome is that GPS shows transformative data and could become the new standard for AML treatments, shortly after data the stock will probably be $10-20 per share and the buyout bidding war will begin. Perma bulls think this can be sold for $100+ a share, I’d say with good data, a short squeeze (did I mention it’s heavily shorted?) and institutions jumping in heavily we could see $50+ but not sure about $100. Either way do your own dd but mainly ignore the original poster that says the price action is worrisome LMAO. Binary events are once again binary, price fluctuation gives more buying opportunities when newbies like them^^^^ don’t realize that. NFA DYOD (Just to disclose I have a position of 17,741 shares $1.63. If I lose it all I’ll survive, if I make a killing here I’ll be a happy camper)

Orange_Codex

Potentially just a big buy. It happened to INTS and SLS in the last few days.

Orange_Codex

Very confident. Finances are solid, institutional backing is solid, past trial performance for the lead drug (GPS) is solid. We also know patients are surviving far longer than SLS expected because news is supposed to drop when the eightieth patient in the cohort dies. It's a year overdue.

newbiescreby

is SLS pure gamble or you have some convition? I have been thinking about this one for a while

Orange_Codex

Got bored scalping so I bought some SLS and am not trading again today.

MrKingTarzan

 +56.7% revenue growth YTD → For a small cap, that’s basically liftoff. ✔ +29% YoY in Q3 → Consistent growth, not a one-time spike. ✔ +671% increase in the SLS segment → This is the headline. Insane number. ✔ Losses reduced from –3.6M → –1.0M → Clearly moving toward break-even by 2026. ✔ Share buybacks at $1.45–$1.81 → The company itself is buying shares. Huge bullish signal. ✔ $11.8M cash on hand → Enough fuel for growth — not in survival mode. How are those bad earnings and they punish the price premarket?

MrKingTarzan

 +56.7% revenue growth YTD → For a small cap, that’s basically liftoff. ✔ +29% YoY in Q3 → Consistent growth, not a one-time spike. ✔ +671% increase in the SLS segment → This is the headline. Insane number. ✔ Losses reduced from –3.6M → –1.0M → Clearly moving toward break-even by 2026. ✔ Share buybacks at $1.45–$1.81 → The company itself is buying shares. Huge bullish signal. ✔ $11.8M cash on hand → Enough fuel for growth — not in survival mode. How are those bad earnings and they punish the price premarket?

AccordingMedicine129

SLS is straight dog water. Waste your money if you want

ohgodthehorror95

SLS has a known history of popping and dropping for literally no reason whatsoever. Until I see a press release, I'm not touching it

Orange_Codex

SLS up to something.

Sensitive-Radish-292

I've been looking into SLS some time ago because I got invited into the SLS cult discord, I assume you're from the same cult. So here are my two cents on SLS: Stay away. There is literally 0% chance someone will buy them out because they have an active warrant inducement program. No company will buy off a company that has such obligations and if they will it will be for pennies. Anyone who tells you otherwise is hanging a carrot on a stick in front of you. You are only risking getting diluted.. if you want to buy in, buy in after they dilute and the price halves.

BrightLengthiness853

$SLS is the next play

bruceyj

Makes sense. I was going through their previous earnings reports and saw mentions of SLS. Appreciate your insight

ElmoLovesGrover

I don't like to bet on a big pharma partnership with these microbitechs because it is uncommon for big pharma aro partner up with microcaps who are low on cash. Nevertheless, it does happen sometimes. SLS is the kind of company that big pharm would make a exception for and its worth noting that Merck is already working with SLS on the clinical trials of GPS in combination with Mercks Pembrolizumab. I can see Merck moving ahead with an equity stake to help fund clinical trials since its drug is in some of the trials anyway.

ElmoLovesGrover

For a small biotech SLS is good stuff. I agree that GPS looks good, and SLS009 (met its Phase 2 endpoints, Phase 3 planned to start 2026) is good. They have maybe 9 or 10 months of cash left so dilution is real possibility. I would call it high risk, but not so risky as to be a speculative play. Again dilution in 2026 is likely though.

KekWagon

Reminds me of SLS, I like it

thepoisonpoodle

Thanks for the update. The next to days there is attention to other stocks. NfE, MSAI, RZLV, CTM, BURU... I will reinvest the gains from NFE into SLS. And then after that into PCSA. If this plan will workout.

thepoisonpoodle

Yeah. Currently not invested. Waiting on the NFE earnings to get more money to invest into SLS.

Orange_Codex

SLS gang, who's up?

Acrobatic-Repair-239

I’ve been DCAing into $UNH and have a small-decent sized position $SLS I’ve been adding too as well

shaqballs

SLS is a significantly better buy. The two companies don’t compare trust me. RVPH is fine but SLS is the best biotech buy on the market. Wildly undervalued, heavily shorted, major news before end of the year and a buyout would change anyone holding its lives. Just sayin

Orange_Codex

I'm in both and think SLS is better. The main selling point of RVPH's lead drug (brilaroxazine) is a negative symptom profile. Its clinical performance and range is comparable to other anti-psychotics. That makes FDA approval less certain, and puts a question mark over whether American insurers will cover it. SLS's GPS is exceptional at improving survivability for a wide variety of cancers not covered by any other single treatment. It is so effective trial results have been delayed by more than a year because the eightieth patient has survived much longer than expected. Alongside INTS's INVINCIBLE program, GPS is the closest thing to an all-purpose 'cure for cancer' beyond the proof-of-concept stage.

borjan13

RVPH seems better, but SLS for sure is another one.

shaqballs

Anyone looking for a 6 months to a year hold needs to get on SLS. It’s a gamble but it’s likely to succeed. Two drugs that can save lives and one of them (GPS) might be a miracle drug based off how the trial looks. Buyout would be 25-50x the current SP. Not saying it’ll happen but it’s the best biotech buy out there right now IMO NFA

Orange_Codex

SLS will have *great* data for its lead drug (GPS). We know this because GPS is a survivability-booster. The event triggering data release is the 80th death among treated patients. It was expected last year. Still no sign of it.

Leonlarage

Bro, $SLS !

steadyeddy_10

Should have done that with SLS instead

firechicken23

Just googled it, they are backed by a really good CMO (chief medical officer, the guy who actually oversees research) and an OK CEO. The product itself however is really... not fantastic looking. they are burning case on 3 phase 3 clinical trials, notorious for being the most expensive of the phases, and only one of them has data that I personally would say "looks good" This isnt a suggestion to invest or not, frankly the market right now is based on hopes and dreams, but I personally will not be investing. I am currently in RZLT, RVPH, and SLS (this last one I am not as confident in). again, not financial advice.

Brilliant-Active9275

if INTS did 500% today after publishing their results. Yall need to check out $SLS 10x easy.

Orange_Codex

Partly. Its neo-antigen cocktail has achieved results not seen before among neo-antigen sarcoma therapies. Phases I, II, and III (preliminary) have seen it outperform competitors by 80-100%. But that makes it the best treatment for *one* tumour type. It is not 'a cure for cancer.' The closest thing to a generalised cancer cure is SLS's GPS.

Orange_Codex

If SLS and BCTX both pop 150%+ I can get the number of INTS shares I originally had during its next offering. 

Orange_Codex

Profits are in SLS so it's not (yet) a lost cause.

Orange_Codex

The end of REGAL Phase 3 will be by E.O.Y. It has an estimated completion date of New Year's Eve and they've delayed several times. Once the Phase 3 data is in, SLS can seek FDA approval. It has a bunch of fast-track designations.

Orange_Codex

SLS didn't pop but steadily ramped up. FDA approval is as certain as it ever could be.

Orange_Codex

Stack SLS until E.O.Y.

EnoughWalk7471

You got option B since not specified. Check your dm for other ticker and strategies # 30-Day Medium-Risk Covered Call Analysis (~25 Delta) |Ticker|Current Price|Qty|30-Day Strike|Premium ($)|Yield % (30d)|Annualized %|Assignment Prob %| |:-|:-|:-|:-|:-|:-|:-|:-| |TSLA|$458.72|105|$515.00|$892.50|1.85%|22.2%|24%| |SLS|$2.04|22000|$3.00|$2200.00|4.89%|58.7%|24%| |CTXR|$1.58|16000|No medium-risk CC available|\-|\-|\-|\-| > # Option B: Top 3 Strikes Ranked by Yield vs Delta - Simplified |Ticker|Low Δ Strike (Yield %, Δ)|Medium Δ Strike (Yield %, Δ)|High Δ Strike (Yield %, Δ)|Best Balanced (\~25Δ)| |:-|:-|:-|:-|:-| |TSLA|$545.00 (1.03%, Δ15)|$515.00 (1.85%, Δ24)|$490.00 (3.08%, Δ36)|$515.00 (1.85%, Δ24)| |SLS|N/A|$3.00 (4.89%, Δ24)|$2.50 (7.33%, Δ36)|$3.00 (4.89%, Δ24)| |CTXR|N/A|N/A|$2.00 (11.09%, Δ41)|N/A|

Orange_Codex

SLS presenting Phase 3 and Phase 2 data today. I was going to wheel any profits into WWR, but WWR's warrants at $0.45 make that a lost cause. Instead I'll expand the SLS position.

Orange_Codex

SLS.

timee_bot

View in your timezone: [October 29, 2025 10:00 AM ET][0] [0]: https://timee.io/20251029T1400?tl=Dear%20Sir%20or%20Madam%2C%20it%20is%20about%20SLS

CEO-of-SOXL

No but SLS will

CEO-of-SOXL

Anyone else in $SLS for news this week?

Orange_Codex

Not FOMOing back into GPUS. SLS is where it's at.

Orange_Codex

Here. My dream scenario right now is SLS soars and WWR warrants get exercised (at $0.45) so I can buy much more of it on the cheap.

Orange_Codex

Ditched GPUS for more SLS.

Orange_Codex

Daily 200% pharma pops give me real hope for SLS (29th) and BCTX (E.O.Y.).

BrightLengthiness853

SLS big week

RaZE___SoViEt

There is no question here for **PM Watchlist** : **$ASST** : hit overnight trading limit at 1.54$ in 3 minutes,called entry here at 0.85, congrats to those who’s in, if you can get in at this levels it’s easy 20% swing, don’t get greedy. **$GPUS** **$$IMG** , **$YDKG** --- Weekly plays : **$BITF** **$OPEN** : is still retail favorite and will climb **SLS** : RnD day Oct-29 **$AUTL** : Oct-28 treatment poster meeting . **$RR** : https://preview.redd.it/icsy2ug4ykxf1.jpeg?width=2640&format=pjpg&auto=webp&s=256ff2e41ecf3330ffc512546ad50b7c5d54c693

snipsnaps1_9

I don't see the numbers behind any of these. I'm still looking at DDD, SLS, and SNBR (not a penny yet but close to it with low volume and ~45% si)

ewhgrtfgh

YYAI will be doing a reverse split soon, something I advised all of the current bag holders before they lost 75% of their investment. If you buy that stock now you will likely lose 50% in the short term and will be bag holding for many months ahead. ASST seems totally like a momentum play. I have no idea the fundamentals. But with the wave upon wave of pump and dumps recently I would say the credibility is at an all time low. That being said I’m holding NUAI. Company actually has a decent CEO and may be onto something as soon as this quarter. Also SLS, and POET are good as well.

Orange_Codex

I'll sell SLS to hop on ASST in pre-market, then pivot any gains back to SLS.

Super-Activity-4675

SLS might an interesting play this week. They are in stage 3 clinical trials for an anti-cancer biologic that treats AML (competing with an 18B drug Keytruda). It also has positive indications for a number of different cancers. They had an interim readout that was very positive, and when the 80th event is read out (any time now), if it's still positive they get a fast track to approval. They have a call on the 29th just after the market opens implying some sort of news. The chart itself looks primed to run up to 3 or maybe 4 on a normal cycle coupled with insider buying and institutions starting to pick them up. I'd say if the news was really good, it should probably hold a similar value to IBRX (which currently sits about 10x higher than their market cap) given they're competing with Keytruda for a different cancer and have similar safety results. Depending on who you read, the short float is between 20 and 40%. I don't know if this is a true squeeze compared to some of the float numbers I see around here, as you're definitely playing the news with some risk, but with that type of short float, the stock has the potential for a violent spike upwards that often happens in this space.

Orange_Codex

SLS (Sellas Life Sciences) is presenting two pipeline drugs at a virtual R&D conference on October 29th at 10:00 (EST). This isn't the big boom, but if data for lead drug GPS continues to be good final approval will be a *rocket*.

Lazy_Inflation_6035

I'm all in on buru, SLS and Vivk. Hoping for small gains. I've learned that take the gains when they're there. 

Prestigious-Duck-189

SLS Total Short Volume since 10/15/2025: ≈ 7,860,000 Current Short: ≈ 23,051,000 Outstanding Shares: ≈ 104,993,000 (public float ≈ 105 M of 193 M FD) Short %: ≈ 22.0 % Days to Cover: 4.6 Borrow Fee (CTB): 38.7 % ↑ Shares Available to Short: ≈ 4,000 ↓ Big catalyst coming this Wednesday the 29th with the R&D event. Great data is expected.

Orange_Codex

SLS ($2.00). A Phase 3 immuno-oncology biotech with major institutional ownership, upcoming catalysts, and an overbearing short float. BCTX ($13.82). Another Phase 3 immuno-oncology biotech with major institutional ownership, a superstar drug, tiny volume, and a diminutive, locked-up float. A penny at heart because it did a reverse split back in August.

ChapterFearless7206

SLS has no revenue

newtownkid

she's cooking today but I'm already balls deep in another speculative pharma trade (SLS)

sibeliusfan

Let me check Boeing’s timeline… something something Starliner? Wonder what happened to it. I don’t cheer for monopolies because a lack of competition leads to price increases, but in this case I make an exception. Starship and SpaceX are the only chance we have at a revival of space exploration without government bureaucracy (let me remind you that Starship is 20x cheaper than the SLS, and will be almost 100x cheaper when operational). They need the income from Starlink to fund their development, and I’m down for that. Like come on, a fucking 120 meter tall rocket being caught by a tower is insane. Also, isn’t it a bit hypocritical of you to say that considering Airbus and Boeing are some of the biggest monopolies in the world?

RaZE___SoViEt

**$EONR** & **$PED** : Oil plays 🛢️ **$LITM** : Tiny float ☢️ : https://www.newsfilecorp.com/release/271259/Snow-Lake-Launches-Kadmos-Energy-Services-Entering-the-Nuclear-Power-Sector-with-a-Bold-Vision **$SLS** : RnD Day Oct 29 Catalyst PM Watchlist: **$NDLS** : No news new food meme pump? 🍜 **YDKG** : 🇨🇳

BreakfastSpecials

I think SLS has Early-stage squeeze potential

Acrobatic_Force7954

I like SLS, wasn’t on my radar but it’s definitely worth it. For context, lots of these players will pop in the 4th quarter but I’m eyeing the short floats right now and SVRE fits the mold just like WLDS had a month ago

BreakfastSpecials

No $SLS??

Ok-Print-1906

Am in SLS. Will continue to add at the dips.

Orange_Codex

SLS. Big institutional buy-ins recently (Blackrock), high insider ownership, and positive Phase 3 clinical data expected. You've seen those biotechs doing 100-300% recently? This will be one. I also think BITF, LAES, and WWR will recover previous highs (in that order), and KRKNF is going places too. Also B&M (a European retailer) suffered a huge overreaction the other day. Juicy dividends and a probable seasonal run-up.

Orange_Codex

I sold it for BCTX earlier but am confident SLS can 1.5x with a news drop.

Dangerous_Ice2839

No SLS?

Orange_Codex

SLS should do at least 130% when news drops. RANI and NERV have much smaller floats, but the proportions locked-up are similar.

Dull-Cheetah-4364

I’ve been following $SLS a lot over the last few days. Look into it

steadyeddy_10

SLS

Professional_Task694

Any thoughts on SLS? Bought this morning on the dip and has pretty much traded sideways since. Wanted to see if any of y’all have positions and whats y’alls PT?

steadyeddy_10

SLS

RaZE___SoViEt

$BYND in this on Friday dip, failing company, shorted, artificial hype. Do not get greedy here, toxic Sec fillings. Money to be made though. $OPEN : still open **$AUTL** : **Oct-24** : https://www.sec.gov/Archives/edgar/data/1390478/000201238325002700/xslSCHEDULE_13G_X01/primary_doc.xml ___ **$SLS** : **Oct 17** : Black rock 5.5% : https://www.sec.gov/Archives/edgar/data/1390478/000201238325002700/xslSCHEDULE_13G_X01/primary_doc.xml **Oct-17/21** : Positive results presentation: https://www.sec.gov/Archives/edgar/data/1390478/000201238325002700/xslSCHEDULE_13G_X01/primary_doc.xml ___ Premarket: $LNKS : Continuation : AH PR: https://www.sec.gov/Archives/edgar/data/1972074/000121390025099733/ea026160201ex99-1_linkers.htm $SLRX $YYAI

Orange_Codex

I'm hoping DFLI boosts my SLS funds.

ImaginationBroad2590

Anyone considering SLS? Pretty decent squeeze setup this week: 45M in future call volume that will force the MMs to cover with upwards price pressure, about 20M short shares that need to cover as well. Blackrock disclosed some share buying Friday that drove the stock up AH, and the longs are looking forward to this week. We’ve also got some major phase 3 results being announced soon and a couple other potential PRs that could be dropped whenever. It’s really going to take off

ridethecashwave

Going to up my SLS stake at some point soon. Hope I get a chance

yahoo_determines

$SLS popped 40% after hours Friday but I can't find any news

FantasticPeanut4853

SLS

Apegg

Seeing a lot of chatter about SLS.  Looks like a binary biotech play.  Any thoughts?

ooqua

😂go all in on SLS🚀

ooqua

go all in on SLS🚀